Elevation Oncology Inc
NASDAQ:ELEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bank IBK Indonesia Tbk PT
IDX:AGRS
|
ID |
|
S
|
Siemens AG
BMV:SIEN
|
DE |
Elevation Oncology Inc
Non-Reccuring Items
Elevation Oncology Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elevation Oncology Inc
NASDAQ:ELEV
|
Non-Reccuring Items
-$942k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$5.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$7.1B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-61%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Non-Reccuring Items
-$7.2m
|
CAGR 3-Years
23%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$512m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-72%
|
|
Elevation Oncology Inc
Glance View
Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.
See Also
What is Elevation Oncology Inc's Non-Reccuring Items?
Non-Reccuring Items
-942k
USD
Based on the financial report for Dec 31, 2024, Elevation Oncology Inc's Non-Reccuring Items amounts to -942k USD.
What is Elevation Oncology Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
82%
Over the last year, the Non-Reccuring Items growth was 82%.
